RNA, U6 small nuclear 481, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-481P profile across patient tissues and cancer cell-line models. RNU6-481P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU6-481P is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RNU6-481P RNA expression shows 15,791 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where RNU6-481P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-481P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-481P survival associations across molecular data types. RNU6-481P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-481P RNA expression–survival associations across cancer types. High RNU6-481P expression shows unfavorable associations in ACC and KICH, but favorable associations in SKCM, HNSC, BLCA and CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU6-481P RNA expression.
This table summarizes RNU6-481P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-481P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-481P shows lower tumor expression in THCA, LUAD, KICH and READ and higher tumor expression in BLCA and LIHC. The THCA box plot shows higher RNU6-481P RNA expression in normal versus tumor tissue (log2 FC = −1.176, t-test p < 0.001).
This table shows molecular features associated with RNU6-481P in patient tissues and cancer cell lines. In patient samples, RNU6-481P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
